Journal
NATURE REVIEWS RHEUMATOLOGY
Volume 17, Issue 3, Pages 133-134Publisher
NATURE RESEARCH
DOI: 10.1038/s41584-021-00575-5
Keywords
-
Categories
Ask authors/readers for more resources
JAK inhibitors are now a standard treatment for rheumatoid arthritis patients, but concerns about an increased risk of venous thromboembolism have tempered enthusiasm for their use in clinical settings.
Janus kinase (JAK) inhibitors have become standard treatment for patients with rheumatoid arthritis who do not respond well to other DMARDs. Concerns have been raised over an increased risk of venous thromboembolism with JAK inhibitors, tempering enthusiasm for their use in the clinic, but are these concerns justified?
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available